Tag Archives: HEA

COVID-19 Sparks Boom in Digital Hospitals with Smart Technologies, Improving Quality of Care

Digital hospitals enhance patient care and improve healthcare staff’s efficiency and productivity, finds Frost & Sullivan

SANTA CLARA, Calif., Oct. 22, 2020 — Frost & Sullivan’s recent analysis, Digital Hospitals: Creating Growth Opportunities in Patient Care during the COVID-19 Pandemic and Beyond, finds that digital hospitals that deploy smart technologies, such as artificial intelligence (AI), remote health monitoring, and robotics, deliver higher standards of patient care and hassle-free experiences for health professionals. The adoption of such advanced technologies has witnessed strong traction during the COVID-19 pandemic. There is a massive influx of patients, and traditional hospitals are struggling to provide quality care and ensure health professionals’ safety. Technology adoption is expected to rise further in the next two to three years due to higher-quality care and significant productivity gains.

COVID-19 Sparks Boom in Digital Hospitals with Smart Technologies, Improving Quality of Care
COVID-19 Sparks Boom in Digital Hospitals with Smart Technologies, Improving Quality of Care

For further information on this analysis, please visit: http://frost.ly/4ou.

"Digital hospitals address limitations of traditional providers such as centralized care delivery, closed systems, fee-for-service care models and a reactive approach through decentralized care, interoperable systems, and outcome-driven and proactive approaches," said Neeraj Nitin Jadhav, Technical Insights Senior Research Analyst at Frost & Sullivan. "To improve patients’ satisfaction levels at every step of care delivery during their stay in the facility, digital hospitals are using technologies like hospital navigation, intelligent imaging platforms, medical robots, remote patient monitoring tools, medication management applications, communication tools, electronic health record (EHR) applications, and clinical decision support solutions."

Jadhav added: "Digital hospital operators need to focus on building internal architecture, especially staff workstations and patient rooms that follow evidence-based design (EBD), as these are the areas where clinical decisions are made and care is provided, respectively. Additionally, decentralized healthcare staff workstations outside the patient rooms can allow the staff to be closer to the point of care rather than a centralized area, which increases the travel distance for the health professionals." 

The increasing adoption of digital technologies in hospitals presents immense growth prospects for market participants in the digital hospital space, including:

  • Deploying smart patient tracking systems to manage patient flow, treatment progress, discharge, and other hospital processes.
  • Proper training and implementation of EHRs can improve a hospital’s ability to provide high-quality care and address health disparities in the population.
  • Use of AI to make supply chain management more sophisticated as the algorithms process huge volumes of hospital data to identify trends and provide insights to improve the facilities’ efficiency and quality of care.
  • Analyze data obtained from different hospital departments to empower local healthcare teams.

Digital Hospitals: Creating Growth Opportunities in Patient Care during the COVID-19 Pandemic and Beyond is the latest addition to Frost & Sullivan’s Technical Insights research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Digital Hospitals: Creating Growth Opportunities in Patient Care during the COVID-19 Pandemic and Beyond

D9AD

Contact:
Mariana Fernandez
Corporate Communications
Phone: +1 (210) 348.1012
Email: mariana.fernandez@frost.com 
https://www.frost.com

Related Links :

Frost New Home page v2

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

HONG KONG, Oct. 15, 2020 — Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico’s state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho’s expertise in drug development, aimed to extend the human healthspan.

Insilico partners with Taisho
Insilico partners with Taisho

"We’re delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho’s validation platform to explore the new space of anti-aging solutions," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico’s co-ownership of the successfully developed programs under agreed payment.

"It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/

Media Contact

For further information, images or interviews, please contact:

ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Photo – https://mma.prnasia.com/media2/1312850/insilico_taisho.jpg?p=medium600  

Related Links :

http://insilico.com

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases


Strategic partnership in brain imaging and AI

PARIS, MONTREAL, and QUEBEC CITY, Oct. 13, 2020

  • Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE
  • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada
  • A unique technology alliance to improve clinical trials performance and personalize brain diseases management

QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval. The objective of this strategic collaboration is to combine TPMD’s technologies, patents and expertise with Qynapse’s know-how and product line – and thus form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

The QyScore application
The QyScore application

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (McGill University, Montreal, Canada) and Prof. Simon Duchesne (Université Laval, Quebec City, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and AI applied to this field, supported by more than 500 publications and scientific communications. These technologies are already being used in Canada by leading research consortia and private international players in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore® medical device to clinical centers in Europe and the United States. Its platform is also used in clinical trials involving dozens of centers worldwide. The collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software to other brain diseases such as stroke, epilepsy, autism, schizophrenia, and head trauma – and also to develop new software to predict clinical progression for individual patients and optimize enrollment in clinical trials.

QYNAPSE’s acquisition of TPMD covers 15 patents, including 9 issued in the United States and Canada, grouped into nine technological asset families. The founders of TPMD will join QYNAPSE’s scientific board, setting the stage for a long-term collaboration.

According to Prof. Louis Collins: "QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate the regulatory approval and marketing of the technologies we have developed in recent years". Prof. Duchesne adds, "Indeed, with QYNAPSE we will have access to a partner that is already well established in the medical field. We look forward to providing clinicians with the tools they need to improve the accuracy of their diagnosis, facilitate prognosis and guide treatment for diseases such as dementias and cerebrovascular diseases."

"We are delighted to partner with two of the world’s leading experts in brain imaging, and to expand our scientific and clinical collaborations with two major centers of excellence in this field." said Olivier Courrèges, CEO of QYNAPSE. "This collaboration will create a unique technological structure, strengthening our ability to deploy powerful tools to address two major challenges: clinical trial performance and personalized management of brain diseases, which affect more than one in six people worldwide."

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be operated by this new entity.

About QYNAPSE

Founded in 2015, QYNAPSE is a French medical technology company, a spin-off from the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions utilizing the potential of quantitative imaging and artificial intelligence to optimize diagnosis, prognosis and monitoring of patients with neurological diseases.
QYNAPSE is headquartered in Paris (France) and in Boston (USA).
www.qynapse.com 
www.qynapse.com/qyscore-software/ 

About TRUE POSITIVE MEDICAL DEVICES (TPMD)

Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off from the work of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval and Prof. Louis Collins at the Montreal Neurological Institute and McGill University. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based in Montreal and Quebec City (QC, Canada).
www.truepositivemd.com  

Logo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases-2.jpg
Photo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases.jpg

Media Contact
Ysé Sallé de Chou
Qynapse
ysalledechou@qynapse.com

“MUSCLE SUIT Every” PR Campaign Selected as “2020 IN2 SABRE Awards Asia-Pacific” Winner, “2020 SABRE Awards Asia-Pacific” Finalist

TOKYO, Oct. 12, 2020 — Innophys Co., Ltd., which develops and sells wearable work-assisting robot MUSCLE SUIT Every, was selected as a finalist in the "2020 SABRE Awards Asia-Pacific," one of the world’s most prestigious PR awards, on September 24 for its publicity campaign to encourage younger people to present their parents with the product on Father’s Day and Mother’s Day. The company won the honor in addition to winning the "2020 IN2 SABRE Awards Asia-Pacific" on August 26 for the same campaign.

Innophys conducted the PR campaign in April-May in cooperation with BlueCurrent Japan.

(Image1: https://kyodonewsprwire.jp/prwfile/release/M106291/202010065369/_prw_PI1fl_72C5YHS8.jpg)

(Image2: https://kyodonewsprwire.jp/prwfile/release/M106291/202010065369/_prw_PI2fl_z70R17E1.jpg)

(Image3: https://kyodonewsprwire.jp/prwfile/release/M106291/202010065369/_prw_PI3fl_3xAv7Qgy.jpg)

About MUSCLE SUIT Every:

MUSCLE SUIT Every is a wearable work-assisting robotic suit developed by Innophys Co., Ltd., a venture company that originated in Tokyo University of Science. The robotic exoskeleton suit uses pneumatic artificial muscle to assist movements, such as lifting up heavy items or a person and maintaining a half-crouching position, with up to 25.5kgf of assistive force to lighten the load on the backs. MUSCLE SUIT Every is excellent in that it can be used for jobs outdoors or with water because the machine does not need electric power. Since it was released in 2014, MUSCLE SUIT Every has been in widespread use at nursing care, farming, manufacturing, distribution and construction sites, and in other labor-intensive activities. By the end of June 2020, MUSCLE SUIT Every has sold over 13,000 units.

The latest model of MUSCLE SUIT Every, which was placed on the market in Japan in November 2019, is the lightest of all MUSCLE SUIT models, at only 3.8 kilograms, while maintaining its capacity to provide auxiliary force up to 25.5kgf. The price of the latest model has been reduced to below 30% of its past models, making it easier for not only corporate customers to introduce the robot for use at work sites but also individual customers to buy the machine to provide nursing care for their elderly family members or grow vegetables at home, among other purposes.

As part of its overseas expansion, the company began to sell MUSCLE SUIT Every in Taiwan this past summer, making it easier for both corporate and individual customers in the region to buy the robotic suit.

MUSCLE SUIT Every official brand website for Taiwan (traditional Chinese characters): https://musclesuit.co.jp/tw/

About the campaign to encourage younger people to present their fathers and mothers with MUSCLE SUIT Every on Father’s and Mother’s Days:

Innophys has been selected as a finalist of the 2020 SABRE Awards Asia-Pacific and winner of the 2020 IN2 SABRE Awards Asia-Pacific for a twitter campaign it conducted in April and May this year for Father’s and Mother’s Days in Japan. In the campaign, those who wanted to present their fathers and mothers with MUSCLE SUIT Every were invited to tweet messages describing the specific scenes where they wanted their fathers and mothers to use the robotic suit with a hashtag, "okuru kinniku" ("muscle as a present"). The company offered MUSCLE SUIT Every to prize winners in the campaign at heavily discounted prices, and MUSCLE SUIT Every was sent directly to the parents of the winners. Many winners subsequently uploaded photos of their parents smiling after receiving the product to their twitter accounts. As a result, information regarding MUSCLE SUIT Every reached over 900,000 people online.

About SABRE Awards, IN2 SABRE Awards:

The SABRE Awards honor is one of the world’s most prestigious PR awards. SABRE, which stands for "Superior Achievement in Branding and Reputation," honors PR campaigns that made outstanding performance in branding and reputation building.

Among the SABRE Awards, the IN2 SABRE Awards, which Innophys won just recently, commends excellent solutions. IN2 stands for "Insight + Innovation."

Innophys’ campaign to encourage younger people to present their parents with MUSCLE SUIT Every was highly commended as a campaign that made effective use of digital media based on the concept of PR-driven business practices, and won the award for the "Best Use of Global Social Networking Platforms."

https://www.provokemedia.com/events-awards/sabre-awards/sabre-awards-asiapacific/2020-in2-sabre-winners

The campaign also made it as a finalist of the 2020 SABRE Awards Asia-Pacific.

https://www.provokemedia.com/events-awards/sabre-awards/sabre-awards-asiapacific/2020-sabre-asia-pacific-finalists

Innophys, as a company based in Japan where the population is rapidly aging as the birthrate is declining, is seeking to ensure as its mission that people lead self-reliant lives. It is determined to continue developing and providing products to help as many people in the world as possible remain active throughout their lives.

Official website: https://innophys.jp/en/

Related Links :

Home

BenQ Launches GW2780T Eye-care Monitor and Monitor Light ScreenBar to Protect Consumers’ Eye Health

BenQ’s advanced eye-care technologies and sleek ergonomic designs power the latest work and study setup in a screen-centric world

SINGAPORE, Oct. 12, 2020 — BenQ, the world-leading provider of digital lifestyle innovations, today launched the GW2780T Eye-care Monitor and Monitor Light ScreenBar, a powerful combination to safeguard eye health for any work and study environment. GW2780T is the 27-inch edition of its popular predecessor GW2480T 24-inch monitor, featuring the latest eye-care technologies and height adjustment stand; complemented by the ScreenBar, an intelligent clip-on monitor light with advanced sensors and dimmable features designed for consumers’ viewing comfort.

BenQ Launches GW2780T Eye-care Monitor and Monitor Light ScreenBar to Protect Consumers' Eye Health
BenQ Launches GW2780T Eye-care Monitor and Monitor Light ScreenBar to Protect Consumers’ Eye Health

With the existing work-from-home regulations due to COVID-19, Singaporeans continue to spend a disproportionate amount of time at their home office, creating a need for intelligent digital products that maintain and protect eye health in our screen-centric world.

"The ongoing pandemic has normalised remote working and learning on a large scale, resulting in an increase in average screen time for both adult and young digital consumers. The launch of BenQ’s GW2780T Eye-care Monitor and Monitor Light ScreenBar in Singapore is paving the way for new concepts of home productivity and entertainment setups while safeguarding consumers’ eye health," said Jeffrey Liang, President of BenQ Asia Pacific. "The monitor-ScreenBar duo boasts intelligent features and intuitive designs to optimise the productivity corner, a commitment that BenQ continues to uphold for office workers and students who are experiencing higher screen time after the pandemic."

GW2780T – Eye-care monitor designed for remote working and learning

The latest model in BenQ’s G-Series LED monitors, the GW2780T Eye-care Monitor offers the user many vision health-focused features, including BenQ’s exclusive Brightness Intelligence Technology (B.I.). As screen time increases, computer users are more susceptible to eyestrain caused by improper lighting from ambient light and display light, as well as reflection glare. This could potentially contribute to the prevalence of myopia in Singapore, which is currently amongst the highest in the world.

The GW2780T Eye-care Monitor uses B.I. to automatically adjust the screen light to suit the user’s surrounding environment, adapting brightness and enhancing dark areas on the display without overexposing bright regions. 

Engineered for safe and optimal screen time, both the GW2480T and GW2780T Eye-care Monitors offer pairing options with laptop, tablet, and even smart phone, allowing the user to enjoy the comfort of big screen projection, with the help of Flicker-Free Technology and Low Blue Light Technology.

The GW2780T is a valuable addition to any home office or study room as its height adjustment stand allows for optimal customisation in terms of the display height, tilt, pivot, and swivel—all of which ensure that anyone in the family can comfortably maintain a proper viewing distance and correct sitting posture.

ScreenBar – An Amazon US bestseller now available in Singapore

An original invention by BenQ, the ScreenBar is a cutting-edge e-reading monitor light that features exclusive auto-dimming feature, asymmetrical optical design, and a patented clip, removing the need for a lamp base and additional table space.

What makes the Monitor Light ScreenBar top off the line is its 14 adjustable brightness levels and 8 colour temperature levels (from 2.7K to 6.5K), maximising the user’s efficiency and comfort. The auto-dimming feature, thanks to built-in ambient light sensors, detects the surrounding brightness and illuminates the workstation with the proper brightness and colour temperature.

The USB-powered ScreenBar also features an asymmetrical optical design that only illuminates the desk and does not shine on the screen, avoiding reflective glare.

BenQ’s Monitor Light ScreenBar can be paired with a wide range of monitors, offering the user unmatched product versatility and optimal viewing experience regardless of their environment.

The GW2780T Eye-care Monitor and Monitor Light ScreenBar retails at SGD339 and SGD159 (before GST) and are now available exclusively at BenQ Store on Lazada.

Read more about the GW2780T Eye-care Monitor and Monitor Light ScreenBar here.

About BenQ Corporation

Founded on the corporate vision of "Bringing Enjoyment ‘N’ Quality to Life", BenQ Corporation is a world-leading human technology and solutions provider aiming to elevate and enrich every aspect of consumers’ lives. To realize this vision, the company focuses on the aspects that matter most to people today – lifestyle, business, healthcare and education – with the hope of providing people with the means to live better, increase efficiency, feel healthier and enhance learning. Such means include a delightfully broad portfolio of people-driven products and embedded technologies spanning digital projectors, monitors, interactive large-format displays, audio products, cloud consumer products, mobile communications and lifestyle lighting. Because it matters.

GW2780T – Technical Specifications

Display

Screen Size

27

Panel Type

IPS

Backlight Technology ‎

LED backlight

Resolution (max.)

1920×1080

Brightness

250

Native Contrast(typ.)

1000:1

Viewing Angle (L/R;U/D) (CR>=10)

178/178

Response Time

5ms

Aspect Ratio

16:9

Display Colours

16.7 Mil.

Colour Gamut

72% NTSC

Display Area(mm)

597.60×336.20

PPI

93

DCR (Dynamic Contrast Ratio) (typ.)

20,000,000 : 1

Colour Bit

8 bits

Audio

Built-in Speaker

2Wx2

Headphone Jack

Yes

Audio Line In

Yes

Monitor

Product Colour

Black

Colour Temperature

Normal (6500°K) / Reddish (5700°K) / Bluish (9300°K) / User Mode

OSD Language

18 Languages (English / Francais / Deutsch / Italiano / Espanol / Polish / Czech / Hungarian / Romanian / Dutch / Russian / Swedish / Portuguese / Japanese / Chinese / S-Chinese / Arabic/ Korean)

HDCP

1.4

VESA Wall Mount

100×100 (mm)

AMA

Yes

Eye Care

Flicker-free Technology

Yes

Low Blue Light

Yes

Brightness Intelligence (B.I.)

Yes

Connectivity

D-sub

D-sub x1

HDMI

HDMI (v1.4) x1

DisplayPort

DisplayPort (v1.2) x1

Power

Voltage Rating

100 – 240V

Power Supply

Built-in

Power Consumption (on mode.)

32W

Power Consumption (based on Energy Star)

18W

Dimension and Weight

Dimensions (HxWxD mm)

552x612x239 (Highest)

430x612x239 (Lowest)

Net Weight (kg)

6.6

Gross Weight (kg)

8.7

Tilt (down/up)

-5˚ -35˚

Swivel (left/right)

N/A

Pivot

90˚

Height Adjustment (mm)

140

Environmental Standards

Energy Star

Yes

EPEAT

Yes

Compliant Standards

TCO

7.0

Certification

Windows® Compatible

Windows®10, Windows®8.1, Windows®8, Windows®7

ScreenBar – Technical Specifications

Lighting

Light source

Dual colour LED‎

Colour Rendering Index

Ra>95

Illuminance

1000 Lux in the centre (height 45cm)

Luminous Flux

320lm‎

Colour Temperature‎

2700~6500K

Power Input‎

5V USB port‎

Power Consumption

5W (max.)

Materials

Aluminium alloy, Polycarbonate

Dimension

45cm x 9.0cm x 9.2cm

Net Weight

0.53kg

Media Contact

Name: Hans LI Chen
BenQ Corporation
Email: Hans.LI.Chen@BenQ.com

Name: Joel Seet
Ying Communications
Email: Joel.Seet@finnpartners.com  

Photo – https://photos.prnasia.com/prnh/20201009/2945112-1?lang=0

Beko’s first-of-its kind household product line eliminates more than 99% of bacteria and viruses (including coronavirus)


New home appliances line, launched via a virtual experience, uses UV light technology heat and steam for at-home disinfection

ISTANBUL, Oct. 8, 2020 — Beko, Europe’s leading home appliance brand, has developed Hygiene Shield, a ground-breaking portfolio of household products, created in response to emerging consumer needs in the post-lockdown era.

 

HygieneShield Product Line
HygieneShield Product Line

 

The new portfolio includes seven appliances with in-built disinfection programmes and functions to disinfect packaged food and belongings to help consumers adjust to the ‘new normal’ at home. Developed as a result of in-depth consumer research conducted across the globe and with innovative new technology, the Hygiene Shield product line has the power to kill more than 99% of bacteria and viruses (including coronavirus), providing a level of reassurance unrivalled in the market place.

Beko’s consumer research, across 31 countries revealed that one of the primary concerns is hygiene. Many of us are disinfecting supermarket purchases when we get home, worrying about handling mobile phones and keys, or not bringing coats into the house. People have increased the amount of cleaning and laundry in their homes, with some people disinfecting bedding for the first time. 75% of people are cleaning the house more often, 64% are doing more laundry and 68% are paying more attention to the cleanliness of the packaging on purchased products.

The line takes inspiration from nature and uses methods such as steam and heat to enable consumers to achieve excellent hygiene results at home. Arçelik’s CEO Hakan Bulgurlu was joined for a virtual discussion by Arçelik’s CMO, Zeynep Yalım Uzun and guest speakers, medical broadcaster and GP Dr Sarah Jarvis and Christopher Sanderson, Future Laboratory’s Co-founder & CEO to announce the launch.

Hakan Bulgurlu says, "It has been a very difficult year and we believe that now more than ever, everyone should have access to good quality products that care for them and the environment. We are excited to introduce Beko’s latest innovations and our first ever full product line to market. The products have been tailored to help consumers achieve professional levels of hygiene at home and protect them from infections and diseases. Our technologies are being independently tested by Airmid Health Group, a respected biomedical research organization. As of today, HygieneShield washing machines, washer dryers, ovens and refrigerators have been shown to provide more than 99% virus reduction. Airmid tests for UV disinfection cabinet and tumble dryers are in progress and we expect to finalize the testing and certification processes by November. Our dishwashers are being independently tested by Rhine-Waal University of Applied Sciences and the testing and certification process is expected to be completed in October. We hope that our products will give consumers peace of mind that their homes are safe and clean, as we all continue to adjust to the ‘new normal’."

Dr Sarah Jarvis says, "I’ve spoken positively on TV about UV light for disinfection purposes: it has been widely used for sterilisation in hospitals, airplanes and factories for some years. It has also been used in China since April this year. COVID-19 has made us all think about how we live outside the home, with masks and social distancing, but I’m seeing my patients start to think about hygiene in the home, where we are spending so much more of our time. I don’t think we should all be going back to the work place yet – working from home wherever we can will keep us safe and reduce the spread of COVID-19. Keeping things clean is the challenge; I advise my patients to wash towels (especially those from the downstairs loo) and dishcloths more frequently and to wash face masks after every use."

Christopher Sanderson, CEO of Future Laboratory, a trend forecasting consultancy in London, writes in a new report, "The home has played a pivotal role in the recent global crisis, forced to double as office, school, gym, restaurant or even a healthcare setting, our homes have become the front line of our external lives."

Heighten your hygiene experience at home

1.  UV cleaning cabinet

Coronavirus can survive for five days on smooth surfaces, so the cabinet uses UV light technology to clean items that you have used outside the home or are concerned about. Keys, phones, wallets, packaged goods from supermarkets, plastic bags, baby bottles and toys can all be safely cleaned in 20-40-minute cycle with no damage to objects. This clever portable device can live anywhere in the home and its touch display makes it as easy to use.

2.  Combi refrigerator with disinfection drawer

The refrigerator disinfects food items in their original and sealed packaging, eliminating more than 99% of bacteria and viruses in approximately 40 minutes. Instead of wiping down each item you bring home from the supermarket or storing them in a safe place for several days, this refrigerator does it for you. Its separate disinfection drawer above the crisper eliminates viruses, bacteria and germs using UV light technology distributed over the compartment.

3.  Tumble dryer with UV light technology

It isn’t practical to wash your clothes every day, or to wash some styles of clothes in high temperatures but we still want to feel certain that our clothes are hygienic. The tumble dryer eliminates bacteria and viruses and provides disinfection for your laundry in a safe and convenient way. The UV Hygienic Refresh programme refreshes up to six dry pieces of clothing. Moreover, the UV Hygienic Drying programme dries and sanitizes up to 5 kg of washed laundry even clothes that need washing at low temperatures. 

4. & 5.  HygieneShield washing machine and  washer dryer

We don’t know how long the Coronavirus can survive on fabric and many of us are worried about our clothing when we get home. What we do know is that people are washing their clothes for longer at higher temperatures as a result of the pandemic. This can get expensive, isn’t sustainable and risks damaging our favourite clothes.

With a smart algorithm, an additional heater channel and fan system, the hygiene therapy programme fills the drum with hot air to keep the laundry at 60°C to thoroughly sanitize your clothes without water. More than 99% of viruses and bacteria are eliminated from 2 kg of clothes in 58 minutes, saving your money and the planet from the use of chemicals and extra water.

6.  Built-in oven with saturated steam and heat

This oven doesn’t just cook your food but cleans it too. Using the exceptional disinfecting power of saturated steam and heat there are two separate disinfection programmes available with this appliance, both involving heat and steam, working at 70°C and 120°C respectively. Use of the oven at 70°C for 15 minutes will disinfect the surfaces of packaged food and make the outside of baked goods more hygienic, without affecting their taste and structure. Use of the oven at 120°C for 20 minutes will disinfect items like metal bowls and glass products.

7.  HygieneShield dishwasher

People trust their dishwasher much more than hand-washing, and with 79% of us cooking more frequently at home, the dishes can pile up. For extra hygienic results, this machine has a hygiene function with steam and additional hot rinsing functions.

Steam mist generated from using higher temperatures and additional hot rinsing ensures that the entire surface of every dish is perfectly hygienic. Dishwashers with the HygieneIntense function can be used with every program which provides disinfection using higher temperatures of 60°C (during main wash) and 70°C (hot rinsing). The technology also means the temperatures can be held above 60 degrees for 50 minutes to disinfect kitchen items. The Hygiene Intense function provides an additional rinsing step to further increase the levels of hygiene. This technology has been independently tested by Rhine Waal University.

*R&D and testing organization, Ireland

Notes to Editor

About Beko:

Beko is the international home appliance brand of Arçelik operating in more than 140 countries. It offers product lines that include major appliances, air conditioners and small appliances. Beko is the leading freestanding home appliances brand in Europe in the white goods sector and no.1 large home appliances brand in the UK. The brand is Main Partner of FC Barcelona, naming partner of Fenerbahçe Men’s Basketball Team and Official Supplier of European League of Legends Championship (LEC).

Photo – https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus-3.jpg  
Photo – https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus-4.jpg  
Photo – https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus-5.jpg  
Photo – https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus-6.jpg
Photo – https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus.jpg

Logo –

https://techent.tv/wp-content/uploads/2020/10/bekos-first-of-its-kind-household-product-line-eliminates-more-than-99-of-bacteria-and-viruses-including-coronavirus-2.jpg

 

Beko Fridge
Beko Fridge

 

Beko Washer Dryer
Beko Washer Dryer

 

 

Beko UV Disinfection Cabinet
Beko UV Disinfection Cabinet

 

 

Arçelik CEO Hakan Bulgurlu
Arçelik CEO Hakan Bulgurlu

 

 

 

 

 

 

Life-changing medical innovations that makes the impossible possible

STOCKHOLM, Oct. 8, 2020Medical wire that stops the trembling caused by Parkinson’s disease. Precision tools that can manufacture tailored prosthetic limbs durable and flexible enough to race down the slopes. And 3D-printing technologies that can create scull and spinal implants in just a few hours. With new and improved technology, the potential for helping people who suffers from physical disabilities have never been better.

The technological advancements within the medical sector are almost hard to grasp. At global engineering group Sandvik, one of the fastest growing segments today is Medical, where the company develops products and components that are essential in solutions that change people’s lives for the better.

In a series of films, Sandvik is celebrating some truly inspirational people that have been helped to live a normal life again after using advanced medical innovations and solutions. Click here to see them: home.sandvik/life-changing-innovations

"Our products in the medical field are rarely seen since they are often a part of the manufacturing process or imbedded in another device. Now we want to highlight the fascinating work happening within the medical sector and encourage more people and partners to look into some of these solutions and be inspired to advance the world of medical innovations even further," says Jessica Alm, Executive Vice President and Head of Communications at Sandvik Group.

Examples of disabilities where Sandvik’s innovations are a part of the life changing solutions are Diabetes, Parkinson’s disease, Hearing loss and physical injuries caused by accidents. Sandvik’s super thin medical wires, machining tools and cutting-edge knowledge within 3D-printing are important stepstones on the route back to a life with minimum impact from the disability.

But don’t take Sandvik’s word for it. Watch the in-depth films, starring persons that have experienced the emotional roller-coaster that comes with living with a disability, and struggling to find a way back to an everyday life.

For more information, contact: Martin Blomgren, Press and Media Relations Manager, email: martin.blomgren@sandvik.com phone: +46 70 577 0549

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/208/3212624/1316650.pdf

Life-changing medical innovations that makes the impossible possible

 

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

Allscripts enables enterprise-level, interoperability-aided EMR workflow adjustments and the subsequent clinical decision-making from a single window

SANTA CLARA, Calif., Oct. 7, 2020 — Frost & Sullivan has identified Allscripts, a global healthcare IT company, as a growth and innovation top-performing leader in the Frost Radar™: US Healthcare Data Interoperability Market, 2020. Allscripts demonstrates superior interoperability across the entire HIT ecosystem by enabling the direct integration of third-party clinical decision support applications into the company’s platforms through on-premise or cloud deployment models.

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market
Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

The global healthcare data interoperability market is valued at $4.92 billion in 2020, and the US market is projected to contribute $3.3 billion (67.07%). Frost & Sullivan expects departmental interoperability within a health system to remain significant during the COVID-19 pandemic because it facilitates the personalization of administrative, clinical, and financial intervention based on patients’ history of COVID-19 or proximity to regional hotspots.

To download the complimentary Frost Radar, please access: http://frost.ly/4mp.

"During and post-COVID-19, Allscripts’ EMR, patient engagement, population health management (PHM), and revenue cycle management (RCM) solutions can be made part of an integrated offering that can interface with external health systems, solutions and service providers, at scale and in near-real-time," said Koustav Chatterjee, Healthcare Industry Principal at Frost & Sullivan.

"We are honored to be recognized by Frost & Sullivan as an industry pioneer, as this ranking reflects our leadership in innovation and interoperability across the healthcare continuum," said Paul Black, Allscripts Chief Executive Officer. "Each day, our mission is to connect care across patient communities around the globe. At Allscripts, we believe healthcare should be Open, for Everyone™."

Frost & Sullivan found that Allscripts has practical, high-impact services that attain higher levels of scale in the United States. Allscripts is poised for further growth by:

  • Opening API initiatives, which are powered by the largest group of third-party API developers (4,000) in the US.
  • Augmenting its EMR capabilities and integrating cognitive interoperability standards across its HIT workflows.
  • Pioneering enterprise-level, interoperability-aided EMR (Sunrise EMR, TouchWorks® EHR) workflow adjustments and the subsequent clinical decision-making from a single window.
  • Incorporating SMART on FHIR (Fast Healthcare Interoperability Resources) across its product portfolio and strongly advocating the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) provisions (under the 21st Century Cures Act) for interoperability and patient access management.

Frost Radar™: US Healthcare Data Interoperability Market, 2020 provides results from an in-depth analysis built on a 360-degree research methodology where over 50 companies were evaluated. The team of industry analysts identified 11 industry leaders excelling at innovation, most poised for growth and ripe for investment, and recognizes them in the Frost Radar with insight into their innovative offerings, projected growth rates, strengths, and opportunities for the future.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Mariana Fernandez
Corporate Communications
Phone: +1 (210) 348.1012
Email: mariana.fernandez@frost.com

https://www.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/frost-sullivan-recognizes-allscripts-as-a-growth-and-innovation-leader-in-the-united-states-healthcare-data-interoperability-market.jpg 

Related Links :

Frost New Home page v2

Visiopharm Announces Scientific Advisory Board

HOERSHOLM, Denmark, Oct. 6, 2020 — Visiopharm®, the Denmark-based leader in artificial intelligence-driven image analysis, tissue mining, and precision pathology has announced the formation of its scientific advisory board (SAB), comprised of industry experts in digital pathology, quality assessment, oncology, and immunology.

AI-driven Digital Precision Pathology is still a relatively new discipline. Compared to many other battle-tested modalities for diagnostics and research, there has been far less time and influx of resources for research and validation. It will take time, resources, and the sharpest scientific minds to unfold the true potential of this new technology, which has a great promise to fill an unmet need for precision medicine in cancer diagnostics.

"Collaborations within the framework of Scientific Advisory Boards is just one of many ways academia and industry can begin to work constructively together to explore, develop and document this new technology and its potential applications in the development of new drugs and companion diagnostic biomarkers. We are excited to be working with the scientific leaders in our field, under the leadership of Dr. Ralf Huss. And we look forward to contributing to the further advancement of AI-driven precision pathology within this forum," stated Michael Grunkin, CEO of Visiopharm.

Chaired by Ralf Huss M.D., Ph.D., certified Pathologist, professor of pathology, and managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg, Germany, the SAB is composed of ten additional luminaries that have extensive industry experience and bring world-class international expertise.

Ralf Huss, states: "The creation of a Scientific Advisory Board is great next step to leverage Visiopharm’s capabilities on how we practice pathology now and in the future on the highest level of clinical and scientific excellence with consistent and reliable quality. The SAB will steer Visiopharm’s solutions to improve cancer diagnostics, and given the complexity of tissue, find novel insights that are assisted by digital and AI-supported solutions." 

The members of Visiopharm’s SAB are as follows:

Marylin Bui M.D. Ph.D., Senior Member in the Department of Pathology and Scientific Director of Analytic Microscopy Core of Moffitt Cancer Center.  Professor and Director of the Cytopathology Fellowship at the University of South Florida, Tampa, Florida, USA.

Andrew Dodson, Director UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH), London/UK.

James L. Gulley, M.D., Ph.D., F.A.C.P., Chief Genitourinary Malignancies Branch, Head Immunotherapy Group, GMB, Director Medical Oncology Service, Center for Cancer Research, NCI, NIH, Bethesda/Maryland, USA.

David Harrison Ph.D., Professor of Pathology at the University of St. Andrews, UK, Director of iCAIRD.

Anne-Vibeke Lænkholm M.D., Clinical Research Professor and Senior Pathologist at Næstved-Slagelse Hospital, Næstved, Denmark.

Prof. Dr. med. Holger Moch, Director Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland.

Prof. Dr. rer. nat. Elfriede Nößner, Head of Immunoanalytics, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.

Anil Parwani M.D. Ph.D., Professor of Pathology, Vice Chair and Director of Anatomical Pathology, Director of the Digital Pathology, OSU, Columbus/Ohio, USA.

Bert Van der Vegt M.D. Ph.D., Histopathologist, University of Groningen, University Medical Center Groningen, The Netherlands.

Mogens Vyberg M.D., Professor of clinical pathology at the University of Aalborg, Copenhagen, Denmark.

The SAB will work with Visiopharm´s leadership team to provide scientific review and high-level advice to the R&D pipeline. The SAB will be involved in strategic discussions for research and pre-clinical solutions as well as the upcoming next-generation Precision Pathology tools for cancer diagnostics. With plans to accelerate diagnostic product development and establish global regulatory programs, the board will also guide these key initiatives.

Adrian Arechiga, Chief Marketing Officer at Visiopharm, commented, "The newly established SAB is an important step for the exciting future development of our research and diagnostic programs. The board members are pioneers in pathology, cancer research, and immunology, bringing unprecedented expertise, skills, and leading scientific perspectives that will guide Visiopharm´s ambitious growth strategy."

About Visiopharm A/S

Visiopharm® is a world leader in AI-driven Digital Pathology solutions. Visiopharms’ pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.

AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, and the United States. Follow Visiopharm on Linkedin and Twitter. For other news, visit the Visiopharm Newsroom.

CoverMyMeds Lauded by Frost & Sullivan for Seamlessly Connecting the Healthcare Network with Its Industry-leading ePA Platform

CoverMyMeds’ platform streamlines prior authorization processes and reduces the approval time from days to mere minutes

SANTA CLARA, California, Oct. 6, 2020 — Based on its recent analysis of the North American prior authorization (PA) solutions market, Frost & Sullivan recognizes CoverMyMeds with the 2020 North America Product Leadership Award. With its innovative electronic prior authorization (ePA) solution, physicians can submit PA requests up to three times faster than with conventional manual, phone, and fax methods. Its suite of medication access solutions seamlessly connect the healthcare network to help reduce prescription abandonment and improve time-to-therapy.

CoverMyMeds
CoverMyMeds

CoverMyMeds’ integrated and web accessible PA platform streamlines the process for healthcare stakeholders, including providers, payers, pharmacy, and life sciences companies. Its network includes approximately 75% of electronic health records (EHRs), 96% of pharmacies, 750,000 providers, and most health plans. With its novel product, it decreases PA determination times from days to mere minutes. Through continuous innovations, it also provides real-time prescription decision support and patient empowerment solutions.

"The cumbersome, traditional prior authorization process is a clear medication access barrier with an estimated 37% of medications requiring PA being abandoned each year.1 CoverMyMeds is helping to solve this by streamlining the complex process electronically," said Pavel Zhebrouski, Best Practices Research Analyst at Frost & Sullivan. "Their platform is the most reliable in the industry, securely and electronically submitting PA requests between pharmacies, providers and health plans. By using CoverMyMeds, determination time is greatly decreased and can lead to an 80% higher dispense rate for prescriptions in some cases.2"

CoverMyMeds also presents an innovative, tech-driven approach to patient support services that streamlines patient access to specialty therapies and enables end-to-end visibility into the patient journey. Its ability to work across the entire patient journey and its business partnerships with all healthcare stakeholders makes it unique in the market. It leverages various methods such as user interviewing, focus groups, co-creation, user testing of its design concepts, quantitative studies, and design thinking methods with all stakeholders to ensure product relevance and customer value.

"As part of the McKesson Corporation, CoverMyMeds has been able to continue growing and reinventing healthcare for millions of patients who need better access to medications," noted Daniel Ruppar, Consulting Director at Frost & Sullivan. "Its responsiveness to both the industry and customer challenges allows it to create best-in-class customer value and achieve sustained leadership in the PA space."

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

1 – CoverMyMeds Data on File, 2020
2 – CoverMyMeds data on file, based on two months of paid and rejected data from PioneerRx, 2019

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

About CoverMyMeds

CoverMyMeds, part of McKesson’s Prescription Technology Solutions, is a fast-growing healthcare technology company that has been recognized as a "Best Place to Work" by Glassdoor and a "Best Company to Work For" by FORTUNE. CoverMyMeds’ solutions help patients get the medications they need to live healthy lives by seamlessly connecting the healthcare network to improve medication access; thereby increasing speed to therapy and reducing prescription abandonment. CoverMyMeds’ network includes 75 percent of electronic health record systems (EHRs), 96 percent of pharmacies, 750,000 providers and most health plans and PBMs. Visit www.covermymeds.com for more information.

Photo – https://mma.prnasia.com/media2/1307170/covermymeds_awards.jpg?p=medium600

Related Links :

Frost New Home page v2